Last Updated: May 3, 2026

sodium benzoate; sodium phenylacetate - Profile


✉ Email this page to a colleague

« Back to Dashboard


What are the generic drug sources for sodium benzoate; sodium phenylacetate and what is the scope of freedom to operate?

Sodium benzoate; sodium phenylacetate is the generic ingredient in three branded drugs marketed by Bausch, Ailex Pharms Llc, Maia Pharms Inc, Navinta Llc, and B Braun, and is included in seven NDAs. Additional information is available in the individual branded drug profile pages.

Summary for sodium benzoate; sodium phenylacetate
US Patents:0
Tradenames:3
Applicants:5
NDAs:7

US Patents and Regulatory Information for sodium benzoate; sodium phenylacetate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bausch AMMONUL sodium benzoate; sodium phenylacetate SOLUTION;INTRAVENOUS 020645-001 Feb 17, 2005 DISCN Yes No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Ailex Pharms Llc SODIUM PHENYLACETATE AND SODIUM BENZOATE sodium benzoate; sodium phenylacetate SOLUTION;INTRAVENOUS 207096-001 Feb 24, 2016 AP RX No Yes ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Maia Pharms Inc SODIUM PHENYLACETATE AND SODIUM BENZOATE sodium benzoate; sodium phenylacetate SOLUTION;INTRAVENOUS 208521-001 May 8, 2017 AP RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Maia Pharms Inc SODIUM PHENYLACETATE AND SODIUM BENZOATE sodium benzoate; sodium phenylacetate SOLUTION;INTRAVENOUS 215025-001 Jun 10, 2021 AP RX Yes Yes ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Navinta Llc SODIUM PHENYLACETATE AND SODIUM BENZOATE sodium benzoate; sodium phenylacetate SOLUTION;INTRAVENOUS 205880-001 Aug 4, 2016 AP RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Navinta Llc SODIUM PHENYLACETATE AND SODIUM BENZOATE sodium benzoate; sodium phenylacetate SOLUTION;INTRAVENOUS 217526-001 Jul 14, 2023 AP RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
B Braun UCEPHAN sodium benzoate; sodium phenylacetate SOLUTION;ORAL 019530-001 Dec 23, 1987 DISCN No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Investment Scenario and Fundamentals Analysis for Sodium Benzoate and Sodium Phenylacetate

Last updated: February 3, 2026

What is the Current Market and Regulatory Status?

Sodium benzoate is an approved preservative used in food, beverages, and medicines globally. Its global market size was valued at approximately USD 400 million in 2022 and is projected to grow at 5-7% annually, driven by increased food safety standards and demand for preservatives [1]. Sodium phenylacetate is primarily a pharmaceutical intermediate used to manage hyperammonemia. It is marketed under critical care indications with limited but stable demand.

Regulatory approvals vary by region. Sodium benzoate has GRAS (Generally Recognized As Safe) status from the US FDA and is accepted in the EU. Sodium phenylacetate requires specific approvals, often through orphan drug designation, for its pharmaceutical applications.

Implication: The market for sodium benzoate is substantial with expanding applications. Sodium phenylacetate remains niche but with consistent demand in clinical settings.

What Are the Supply and Manufacturing Fundamentals?

Raw Material Supply

Sodium benzoate is synthesized from toluene or benzoic acid, both derived from petrochemical sources. The cost of raw materials influences pricing stability; fluctuations depend on oil markets. Global production capacity exceeds 500,000 tons annually, primarily in China, India, and North America [2].

Sodium phenylacetate is produced via chemical synthesis involving phenylacetic acid, produced from phenylacetic acid derivatives. These synthesis pathways are complex but well-established, with no significant raw material shortages reported.

Manufacturing Process and Quality Control

Sodium benzoate manufacturing involves neutralizing benzoic acid with sodium hydroxide, resulting in a straightforward process with high yields (>95%). Quality standards include purity above 99%, and adherence to USP or EP specifications.

Sodium phenylacetate's synthesis includes multiple steps: phenylacetic acid formation, purification, and salt formation. Quality control checks for impurity profiles, residual solvents, and endotoxins, especially for pharmaceutical-grade material.

Cost Structure and Margins

Estimated manufacturing cost for sodium benzoate ranges from USD 1 to 1.50 per kg at scale, with gross margins around 20-30% depending on purity level, regulatory compliance, and regional market conditions. For sodium phenylacetate, costs are higher due to complex synthesis, estimated at USD 8-12 per gram, with margins contingent on prescription pricing.

Implication: Production is chemically straightforward for sodium benzoate, favoring stable margins. Sodium phenylacetate manufacturing is more complex but maintains steady demand in niche markets.

How Do Market Drivers and Competitive Dynamics Shape Investment?

Growth Drivers

  • Food additive regulations tightening globally promote sodium benzoate’s use.
  • Emerging markets with expanding food and beverage industries increase demand.
  • Pharmaceutical applications of sodium phenylacetate for hyperammonemia treatments sustain steady demand.

Competitive Landscape

Major suppliers of sodium benzoate include Chemours, Ajanta Pharma, and local manufacturers in China and India, who benefit from low-cost production. Barriers to entry are low, leading to intense price competition but stable demand.

Sodium phenylacetate has limited suppliers, often manufacturing under licensing or proprietary formulations for specific pharmaceutical clients. Market entry barriers include regulatory approval hurdles and high R&D costs for new indications.

Patent and Regulatory Outlook

  • Sodium benzoate faces no recent patent restrictions. Regulatory standards could tighten around residual benzoates, influencing manufacturing.
  • Sodium phenylacetate’s primary patent life is exhausted; new formulations or delivery methods could extend its commercial lifespan.

Investment Risks

  • Regulatory changes affecting food preservative approvals.
  • Petrochemical price volatility impacting raw material costs.
  • Competition from alternative preservatives (e.g., potassium sorbate, sodium citrate).
  • Patent cliffs or generic competition for pharmaceutical applications.

Implication: Sodium benzoate offers a stable, low-risk investment with moderate growth prospects. Sodium phenylacetate’s niche market limits upside but offers stability in specialized settings.

What Are the Financial and Investment Considerations?

Return on Investment

Sodium benzoate’s high production volume and steady demand support investment in manufacturing capacity or supply chain consolidation. Margins are compressed but compensated by scale.

Sodium phenylacetate investments may involve licensing or development costs for new indications. Returns depend on regulatory success and competitive positioning.

Market Entry and Expansion Opportunities

  • Entering emerging markets with low existing penetration.
  • Developing formulations with higher purity or novel delivery.
  • Acquiring existing manufacturing assets or distribution channels.

Strategic Partnerships and Licensing

Partnering with pharmaceutical companies for sodium phenylacetate formulations could secure steady revenue streams. For sodium benzoate, collaborations might focus on formulation innovations or regulatory acceptance in new regions.

Implication: Investment strategies should balance scale advantages in the benign-preservative market and the niche pharmaceutical market’s stability.

Key Takeaways

  • Sodium benzoate dominates as a food-grade preservative with a global market size of about USD 400 million; growth driven by regulatory standards and emerging markets.
  • Costs are low and production straightforward, resulting in stable margins. Competitive landscape is intense, but high demand sustains profitability.
  • Sodium phenylacetate remains niche, used in specific medical treatments. Its steady demand offers predictable revenue but limited growth prospects.
  • Raw material prices, regulatory changes, and competition are primary risks.
  • Opportunities lie in market expansion, formulation development, and strategic licensing.

FAQs

1. What are the main applications for sodium benzoate?
Primarily used as a preservative in food, beverages, and medicines; also utilized in cosmetics and some industrial products.

2. Can sodium phenylacetate be used for new medical indications?
Potentially, but development requires extensive R&D, clinical trials, and regulatory approvals, making it a high-entry barrier.

3. How does raw material pricing affect profitability?
Volatility in petrochemical raw materials can impact manufacturing costs, especially for sodium benzoate, but large-scale producers often hedge prices.

4. What are the regulatory trends influencing these compounds?
Food safety standards gradually tighten, impacting sodium benzoate use. Pharmaceutical regulations are relatively stable but subject to change for sodium phenylacetate.

5. Is there a significant risk from substitute preservatives?
Yes, alternatives like potassium sorbate or natural preservatives pose competitive threats, especially where clean-label trends emerge.

References

[1] MarketResearch.com, "Global Sodium Benzoate Market," 2023.
[2] ICIS Chemical Business, "Sodium Benzoate Supply Dynamics," 2022.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.